The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Insights into a Phase I/Ia study of venetoclax, ixazomib and dexamethasone for R/R AL amyloidosis
In this video, Michael Rosenzweig, MD, City of Hope, Duarte, CA, shares insights into a Phase I/Ia clinical trial (NCT04847453) exploring the use of an all-oral regimen including venetoclax, ixazomib and dexamethasone for patients with relapsed/refractory (R/R) light chain (AL) amyloidosis who harbor the t(11;14) translocation. Researchers are particularly hopeful about this trial as more than 50% of patients with AL amyloidosis have this translocation and are in need of alternative treatments after first-line therapies. So far, no dose limiting toxicities have been recorded, and the regimen appears to be safe. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
